Table 1.
Demographic data of AD and control cases
| Case No. | Disease | Method | Age at death | Gender | Duration | PM delay (hours:minutes) | Braak and Braak | Aβ load (mature/diffuse) | pH |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Control | IH, ELISA | 38 | M | n/a | 80.35 | 0 | 0:0 | 5.87 |
| 2 | Control | IH | 82 | F | n/a | 72.00 | 3 | 1:2 | 6.03 |
| 3 | Control | IH | 71 | M | n/a | 38.50 | 0 | 0:0 | 6.30 |
| 4 | Control | ELISA | 69 | M | n/a | 171.00 | 1 | 1:2 | 6.63 |
| 5 | Control | ELISA | 99 | F | n/a | 32.05 | 4 | 2:2 | 6.23 |
| 6 | Control | ELISA | 92 | F | n/a | 87.50 | 3 | 1:3 | 6.50 |
| 7 | Control | ELISA | 87 | F | n/a | 51.40 | 1 | 0:1 | 6.17 |
| 8 | Control | ELISA | 95 | F | n/a | 39.00 | 4 | 2:2 | 6.02 |
| 9 | Control | ELISA | 82 | F | n/a | 91.20 | 2 | 1:3 | 6.25 |
| 10 | Control | ELISA | 93 | F | n/a | 29.40 | 3 | 2:3 | 6.43 |
| 11 | Control | IH | 73 | F | n/a | 24.00 | 2 | 1:2 | 5.72 |
| 12 | Control | IH | 68 | F | n/a | 45.05 | 0 | 0:0 | 6.91 |
| 13 | Control | IH | 34 | M | n/a | 14.00 | 0 | 0:0 | n/a |
| 14 | Control | ELISA | 80 | F | n/a | 49.10 | 2 | 0:0 | 5.79 |
| 15 | Sporadic AD | ELISA | 65 | M | 10 | 96.30 | 6 | 3:3 | 6.63 |
| 16 | Sporadic AD | ELISA | 86 | F | 16 | 90.20 | 6 | 3:3 | 6.22 |
| 17 | Sporadic AD | ELISA | 79 | F | 14 | 22.30 | 6 | 3:3 | 5.98 |
| 18 | Sporadic AD | ELISA | 79 | M | 16 | 64.55 | 5 | 2:3 | 6.40 |
| 19 | Sporadic AD | ELISA | 62 | M | 11 | 62.55 | 6 | 3:3 | 6.79 |
| 20 | Sporadic AD | ELISA | 81 | M | 12 | 78.15 | 6 | 3:3 | 6.49 |
| 21 | Sporadic AD | IH, ELISA | 66 | F | 14 | 51.20 | 6 | 3:3 | 6.20 |
| 22 | Sporadic AD | IH, ELISA | 62 | F | 11 | 16.00 | 6 | 3:3 | 6.31 |
| 23 | Sporadic AD | IH | 64 | M | 10 | 77.15 | 6 | 3:2 | 6.58 |
| 24 | Sporadic AD | IH, ELISA | 64 | M | 14 | 32.35 | 6 | 3:3 | 6.29 |
| 25 | Familial AD (PSEN1 Intron 4) | IH | 51 | F | 16 | 33.30 | 6 | 3:3 | 6.31 |
| 26 | Familial AD (V717L APP) | IH | 59 | F | 11 | 89.00 | 6 | 3:3 | 6.44 |
Neurological normal control and AD cases used in study. Cases were used for either immunohistochemistry (IHC) or enzyme‐linked immuno‐sorbent assay (ELISA). Neurofibrillary tangle pathology was staged according to the current pathological criteria (Braak and Braak) and Aβ load expressed according to the severity of the mature and diffuse plaques, where a score of 1 indicates mild deposition; 2 moderate and 3 severe Aβ deposition.